MedTrace Logo

Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women

NCT00830414 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2024-08-19

No results posted yet for this study

Summary

This study compared the rates and extents of medroxyprogesterone absorption from two medroxyprogesterone acetate injection formulations following single 150 mg intramuscular (IM) injections to healthy postmenopausal women.

Conditions

  • Healthy

Interventions

DRUG

medroxyprogesterone acetate

IM Injection

DRUG

medroxyprogesterone acetate

IM injection

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    lead INDUSTRY

Principal Investigators

  • Horst Jurgen Heuer, M.D. · AAI

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2002-09-30
Completion
2002-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830414 on ClinicalTrials.gov